IN2012DN02304A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02304A
IN2012DN02304A IN2304DEN2012A IN2012DN02304A IN 2012DN02304 A IN2012DN02304 A IN 2012DN02304A IN 2304DEN2012 A IN2304DEN2012 A IN 2304DEN2012A IN 2012DN02304 A IN2012DN02304 A IN 2012DN02304A
Authority
IN
India
Prior art keywords
aging
arnox
disorders
recombinant
nadh oxidase
Prior art date
Application number
Inventor
James D Morre
Xiaoyu Tang
Sara Dick
Christiaan Meadows
Dorothy M Morre
Original Assignee
Nox Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nox Technologies Inc filed Critical Nox Technologies Inc
Publication of IN2012DN02304A publication Critical patent/IN2012DN02304A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90209—Oxidoreductases (1.) acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4)

Abstract

Described are cell surface and circulating markers for aging related disorders (specific isoforms of NADH oxidase (arNOX)). Recombinant age-related NADH oxidase isoforms and their coding sequences and methods for detecting arNOX isoform presence and quantitation in tissues and in blood, sera, urine, saliva, perspiration and in other body fluids, are provided. Recombinant arNOX proteins are useful in preparing antigens for use in the generation of monoclonal and polyclonal antibodies as well as immunogenic compositions for diagnosis and treatment of aging disorders. DNA probes based on the DNA sequence information provide may be used to identify individuals at risk for aging disorders and for development of preventative or therapeutic interventions or anti-aging cosmetic or other formulations of benefit in slowing the aging process in mammals.
IN2304DEN2012 2009-08-17 2010-08-17 IN2012DN02304A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23436809P 2009-08-17 2009-08-17
PCT/US2010/045745 WO2011022387A1 (en) 2009-08-17 2010-08-17 Cloning and expression of arnox protein transmembrane 9 superfamily (tm9sf), methods and utility

Publications (1)

Publication Number Publication Date
IN2012DN02304A true IN2012DN02304A (en) 2015-08-21

Family

ID=43607300

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2304DEN2012 IN2012DN02304A (en) 2009-08-17 2010-08-17

Country Status (7)

Country Link
US (1) US20120315629A1 (en)
EP (1) EP2467392A4 (en)
JP (1) JP2013502217A (en)
CN (1) CN102574889A (en)
CA (1) CA2771277A1 (en)
IN (1) IN2012DN02304A (en)
WO (1) WO2011022387A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465939B2 (en) 2010-03-02 2013-06-18 Nox Technologies, Inc. Aging-related circulating particle-associated lipoprotein B oxidase (apoBNOX) and inhibitors thereof
EP3013961A1 (en) * 2013-06-25 2016-05-04 Mor-Nuco Enterprises, Inc. Growth-related enox proteins from plants with yield enhancement potential, sequences and methods
CN114774418B (en) * 2022-04-19 2023-11-14 深圳市人民医院 shRNA molecule and application thereof in knocking down TM9SF2 gene expression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175787A1 (en) * 1997-10-28 2003-09-18 Incyte Corporation Vesicle membrane proteins
WO2005003766A2 (en) * 2003-06-13 2005-01-13 Whitehead Institute For Biomedical Research Methods of regulating metabolism and mitochondrial function
US7473531B1 (en) * 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US8014957B2 (en) * 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
WO2008121324A2 (en) * 2007-03-30 2008-10-09 Abbott Laboratories Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
CN102016587B (en) * 2008-01-25 2015-05-13 汉萨生物医药公司 A new metastatic human tumor associated molecule, methods to detect both activated gene and protein and to interfere with gene expression

Also Published As

Publication number Publication date
WO2011022387A1 (en) 2011-02-24
JP2013502217A (en) 2013-01-24
CN102574889A (en) 2012-07-11
CA2771277A1 (en) 2011-02-24
WO2011022387A8 (en) 2012-03-29
EP2467392A4 (en) 2013-06-19
US20120315629A1 (en) 2012-12-13
EP2467392A1 (en) 2012-06-27

Similar Documents

Publication Publication Date Title
CL2007003649A1 (en) An anti-cd70 human monoclonal antibody associated molecule conjugate; composition comprising the antibody-associated molecule conjugate; method of inhibiting the growth of tumor cells expressing cd70.
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
EP2293078A3 (en) Method for diagnosis of a bacterial infection
WO2008108803A3 (en) Immune cell biosensors and methods of using same
BRPI0811210A2 (en) IMAGE TRAINING AGENT, PHARMACEUTICAL COMPOSITION, METHODS FOR PREPARATION OF A IMAGE TRAINING AGENT, FORMATIC OPTICAL IMAGE FORMATION OF A MAMMALIAN BODY AND DETECTION, STAGE ASSESSMENT, PROGRESS MONITOR MONITORING DIAGNOSIS OR MONITORING DIAGNOSIS COLORRETAL CANCER TREATMENT OF A MAMMALIAN'S BODY, AND, KIT FOR PREPARING PHARMACEUTICAL COMPOSITION.
WO2008103645A3 (en) Prostate cancer and melanoma antigens
MX342791B (en) Elisa for vegf.
EP1855719A4 (en) Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
EP2068929A4 (en) Method for detecting and treating skin disorders
FI2398902T3 (en) Methods and compositions for diagnosis and treatment of cancer
MX2010004251A (en) Anti-bst2 antibody.
NZ609567A (en) Markers of endothelial progenitor cells and uses thereof
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
US20180196064A1 (en) Method of evaluating cellulite and method of evaluating cellulite-effective drug using fibulin-3 and/or sarcoglycan gamma as an indicator
IN2012DN02304A (en)
MX2009001070A (en) Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma.
WO2014117680A3 (en) Use of trpc6 mrna levels in peripheral blood cells for early detection/diagnosis of senile dementia
WO2009091230A3 (en) Protein marker for breast-cancer monitoring, diagnosis and screening, and a breast-cancer monitoring, diagnosis and screening method using the same
BRPI0818957B8 (en) isolated gene, expression vector, genetically modified host cell and method for preparing an immunogenic macromolecule
EP2539709A4 (en) Alzheimer's disease-specific alterations of protein kinase c epsilon (pkc-epsilon) protein levels
MY148542A (en) A method for the assessment of cancer in a biological sample obtained from a subject
HK1112630A1 (en) Antibodies against april as biomarkers for early prognosis of lymphoma patients
WO2011141153A8 (en) Methods for the diagnosis and prognosis of a tumor using bcat1 protein
WO2012144755A3 (en) Composition and kit for the diagnosis of mild cognitive impairment, which measure an expression level of lipocalin-2, and method for providing information for the diagnosis of mild cognitive impairment
WO2010108245A3 (en) Use of leishmania antigens in a diagnostic method, vaccine and therapy for leishmaniasis